Deal 2: Lupin snaps up Temmler's products
This article was originally published in Scrip
Lupin has announced its second acquisition on the trot – this time an asset purchase deal concerning Temmler Pharma GmbH & Co's specialty product portfolio in Germany.
You may also be interested in...
Lupin links with Exeltis, Cresco and Macure to sell the NDM therapy in western and central Europe. Plus deals involving Cipla, GoApptiv, Takeda, Debiopharm, PharmaMar and TTY.
Lupin’s rare disease drug, NaMuscla, has been recommended for marketing authorization in Europe – a key milestone for the firm as it shapes its play in the specialty segment. The company may consider taking NaMuscla to other markets such as Japan as well and also add assets to its neuroscience portfolio.
USV is building on its play in Europe with the acquisition of Juta Pharma in Germany – a market that has been fostering generics alongside supporting innovative medicines.